Friday May 10 | Bloomberg
Endo Loses Bid to Stop Sales of Generic Painkiller Rivals
Endo Health Solutions Inc. lost an effort to stop U.S. sales of generic versions of its extended-release painkiller that don't have tamper-resistant qualities.
Friday May 10 | Customer Interaction Solutions
Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Impax Laboratories, Inc. today announced that the Company will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, at 8:00 a.m. Pacific Standard Time.
Endo Health turns 1Q profit, affirms 2013 forecast
Endo Health Solutions Inc. turned a first-quarter profit, reversing a lost at the start of 2012, when the drug developer absorbed a sizeable pre-tax charge tied to a settlement and license agreement.
3 Healthcare Stock Earnings Snapshots
Impax Laboratories Inc. delivered a profit and beat Wall Street's expectations, AND beat the revenue expectation.
Impax Laboratories PT Lowered to $17.00
The firm currently has a "neutral" rating on the stock. Shares of Impax Laboratories traded down 2.99% during mid-day trading on Thursday, hitting $16.85. Impax Laboratories has a 52 week low of $14.41 and a 52 week high of $27.25. The stock's 50-day moving average is currently $16.05. The company has a market cap of $1.117 billion and a P/E ratio ... (more)
Customer Interaction Solutions
Impax Laboratories 96 Hour Alert: Approximately 96 Hours Remain;...
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $150,000 that they have only until May 6, 2013 to file lead plaintiff applications in a securities class action lawsuit against Impax Laboratories, Inc.
Impax Laboratories Management Discusses Q1 2013 Results - Earnings Call Transcript
Good afternoon. My name is Stephanie, and I will be your conference operator today.
Impax Laboratories Reports First Quarter 2013 Results
Impax Laboratories, Inc. today reported first quarter 2013 adjusted net income of $25.3 million or $0.37 per diluted share, compared to $35.8 million or $0.53 per diluted share in the first quarter 2012.
Impax, GSK end Parkinson's disease partnership
Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.
Impax, GSK end Parkinson's disease partnership
ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.
Generic drugs aren't necessarily the same
Andrew Richards remembers that he had just sat down in front of the TV when the lightning bolt struck.
Glancy Binkow & Goldberg Encourages Investors to Inquire About a Lead ...
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of a class comprising all purchasers of the common stock of Impax Laboratories, Inc.